About the survey
As part of a campaign to raise awareness about the use of biomarkers across Europe, a survey was conducted among ECPC member organisations in a joint effort by the ECPC and the European Alliance for Personalized Medicine (EAPM). The electronic/phone survey, conducted between April – June of 2016, gathered 150 answers from various cancer patients/survivors.
Benefits of using biomarkers
[1] WHO. Environmental Health Criteria 237. Principles for evaluating health risks in children associated with exposure to chemicals. WHO, 2006
[2] Use of ‘-omics’ technologies in the development of personalised medicine, European Commission, 2013
[3] Deverka PA, Vernon J, McLeod HL., Economic opportunities and challenges for pharmacogenomics, Annu Rev Pharmacol Toxicol. 2010
https://ecpc.org/news-events/survey-how-much-do-you-know-about-biomarkers
###
... continued from previous page
o For patients they can improve the risk-benefit profile of new and existing drugs, providing optimized therapy selection in a timely manner, to increase the likelihood of response;
o For the industry they can improve the efficiency and speed of the drug development process;
o For healthcare providers they can offer optimized targeted treatment selection, avoid medical errors and reduce adverse reactions to medicinal products2;
For healthcare systems biomarkers can serve as navigation tools, ensuring that the right patient gets the right treatment at the right time. They are part of a comprehensive movement towards personalized medicine and can help to reduce treatment costs, increase patient response, while ensuring efficient use of scarce health care resources3. This is an integral aspect to the sustainability of future healthcare economics.
41